Date Title Description PDF
10 May 2023 On P&L The Company releases the first quarter 2023 financial results presentation Download
10 May 2023 On P&L The Company releases the press release related to the first quarter 2023 financial results Download
25 Apr 2023 On business and financial situation ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) Download
21 Feb 2023 On business and financial situation The Company releases the full year 2022 financial results presentation. Download
21 Feb 2023 On business and financial situation The Company releases the press release related to the full year 2022 financial results. Download

Pages

Date Title Description PDF
29 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted on 28 March 2022 and end of the share buyback program Download
28 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 21 March 2022 and 25 March 2022 Download
21 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 14 March 2022 and 18 March 2022 Download
14 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 7 March 2022 and 11 March 2022 Download
07 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 28 February 2022 and 4 March 2022 Download

Pages

Date Title Description PDF
08 Jan 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the fourth quarter of 2017 Download
21 Dec 2017 Préstamos, créditos y avales ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies Download
08 Nov 2017 Información sobre Resultados ROVI releases the press release related to the nine-month period ended 30 September 2017 results Download
08 Nov 2017 Información sobre Resultados ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. Download
24 Oct 2017 Otros sobre negocio y situación financiera The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. Download

Pages